Literature DB >> 25483455

Bacterial lysates improve the protective antibody response against respiratory viruses through Toll-like receptor 4.

Silvina Coviello1, Vera Wimmenauer, Fernando P Polack, Pablo M Irusta.   

Abstract

Respiratory viruses cause significant morbidity and mortality in infants and young children worldwide. Current strategies to modulate the immune system and prevent or treat respiratory viral infections in this age group have shown limited success. Here, we demonstrate that a lysate derived from Gram-positive and Gram-negative organisms positively modulates protective antibody responses against both respiratory syncytial virus (RSV) and influenza virus in murine models of infection. Interestingly, despite the complex mixture of Toll-like receptor (TLR) agonists present in the bacterial lysate, the modulatory effects were mostly dependent on TLR4 signaling. Our results indicate that the use of simple formulations of TLR-agonists can significantly improve the immune response against critical pediatric respiratory pathogens.

Entities:  

Keywords:  RSV; adjuvants; bacterial; extracts; immunomodulators; influenza; lysates; respiratory; virus

Mesh:

Substances:

Year:  2014        PMID: 25483455      PMCID: PMC5443103          DOI: 10.4161/hv.29784

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  35 in total

Review 1.  Innate immune recognition.

Authors:  Charles A Janeway; Ruslan Medzhitov
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

2.  The impact of influenza-associated respiratory illnesses on hospitalizations, physician visits, emergency room visits, and mortality.

Authors:  Verena H Menec; Charlyn Black; Leonard MacWilliam; Fred Y Aoki
Journal:  Can J Public Health       Date:  2003 Jan-Feb

Review 3.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Nat Immunol       Date:  2010-04-20       Impact factor: 25.606

4.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

Authors:  H W Kim; J G Canchola; C D Brandt; G Pyles; R M Chanock; K Jensen; R H Parrott
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

5.  Oral application of bacterial lysate in infancy decreases the risk of atopic dermatitis in children with 1 atopic parent in a randomized, placebo-controlled trial.

Authors:  Susanne Lau; Kerstin Gerhold; Kurt Zimmermann; Charlotte W Ockeloen; Siri Rossberg; Petra Wagner; Claudia Sulser; Rita Bunikowski; Imke Witt; Juliane Wauer; John Beschorner; Georg Menke; Eckard Hamelmann; Ulrich Wahn
Journal:  J Allergy Clin Immunol       Date:  2012-04       Impact factor: 10.793

6.  Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus.

Authors:  B S Graham; G S Henderson; Y W Tang; X Lu; K M Neuzil; D G Colley
Journal:  J Immunol       Date:  1993-08-15       Impact factor: 5.422

7.  A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles.

Authors:  Fernando P Polack; Scott J Hoffman; Gonzalo Crujeiras; Diane E Griffin
Journal:  Nat Med       Date:  2003-08-17       Impact factor: 53.440

Review 8.  Toll-like receptors.

Authors:  Kiyoshi Takeda; Tsuneyasu Kaisho; Shizuo Akira
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

9.  A synthetic adjuvant to enhance and expand immune responses to influenza vaccines.

Authors:  Rhea N Coler; Susan L Baldwin; Narek Shaverdian; Sylvie Bertholet; Steven J Reed; Vanitha S Raman; Xiuhua Lu; Joshua DeVos; Kathy Hancock; Jacqueline M Katz; Thomas S Vedvick; Malcolm S Duthie; Christopher H Clegg; Neal Van Hoeven; Steven G Reed
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

10.  Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes.

Authors:  Ana Clara Monsalvo; Juan P Batalle; M Florencia Lopez; Jens C Krause; Jennifer Klemenc; Johanna Zea Hernandez; Bernardo Maskin; Jimena Bugna; Carlos Rubinstein; Leandro Aguilar; Liliana Dalurzo; Romina Libster; Vilma Savy; Elsa Baumeister; Liliana Aguilar; Graciela Cabral; Julia Font; Liliana Solari; Kevin P Weller; Joyce Johnson; Marcela Echavarria; Kathryn M Edwards; James D Chappell; James E Crowe; John V Williams; Guillermina A Melendi; Fernando P Polack
Journal:  Nat Med       Date:  2010-12-05       Impact factor: 53.440

View more
  5 in total

1.  A Case-Control Study on the Changes in Natural Killer Cell Activity following Administration of Polyvalent Mechanical Bacterial Lysate in Korean Adults with Recurrent Respiratory Tract Infection.

Authors:  Yun Kyong Lee; Ji-Hee Haam; Eunkyung Suh; Sung Hoon Cho; Young-Sang Kim
Journal:  J Clin Med       Date:  2022-05-26       Impact factor: 4.964

2.  Broncho Vaxom (OM-85) modulates rhinovirus docking proteins on human airway epithelial cells via Erk1/2 mitogen activated protein kinase and cAMP.

Authors:  Michael Roth; Christian Pasquali; Daiana Stolz; Michael Tamm
Journal:  PLoS One       Date:  2017-11-28       Impact factor: 3.240

Review 3.  Neutrophil Extracellular Traps (NETs) and Damage-Associated Molecular Patterns (DAMPs): Two Potential Targets for COVID-19 Treatment.

Authors:  Sebastiano Cicco; Gerolamo Cicco; Vito Racanelli; Angelo Vacca
Journal:  Mediators Inflamm       Date:  2020-07-16       Impact factor: 4.711

Review 4.  Interrupting the Conversation: Implications for Crosstalk Between Viral and Bacterial Infections in the Asthmatic Airway.

Authors:  Jodie Ackland; Alastair Watson; Tom M A Wilkinson; Karl J Staples
Journal:  Front Allergy       Date:  2021-10-26

Review 5.  Promising Immunomodulatory Effects of Bacterial Lysates in Allergic Diseases.

Authors:  Agnieszka Kaczynska; Martyna Klosinska; Kamil Janeczek; Michał Zarobkiewicz; Andrzej Emeryk
Journal:  Front Immunol       Date:  2022-06-22       Impact factor: 8.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.